{"id":18408,"date":"2026-04-16T23:57:37","date_gmt":"2026-04-16T23:57:37","guid":{"rendered":"https:\/\/worldbodybuildingnews.com\/?p=18408"},"modified":"2026-04-16T23:57:37","modified_gmt":"2026-04-16T23:57:37","slug":"what-happens-when-you-stop-ozempic-or-mounjaro-new-study-reveals-surprising-weight-loss-results","status":"publish","type":"post","link":"https:\/\/worldbodybuildingnews.com\/?p=18408","title":{"rendered":"What Happens When You Stop Ozempic or Mounjaro? New Study Reveals Surprising Weight-Loss Results"},"content":{"rendered":"

<\/p>\n

\n

Injectable GLP-1 hormone agonists like Ozempic and Mounjaro are known to reduce appetite and can result in significant weight loss, but what happens when you stop taking them? A new study from the Cleveland Clinic<\/a> looked at almost 8,000 patients to find out, and the results are in. The new study, published by the Journal of Diabetes, Obesity and Metabolism comes after a previous analysis suggested that people tend to regain their unwanted weight<\/a> quickly after discontinuing use. While that previous review had been based on set programs and randomized trials, the new research looked at what was happening in the real world, where people are able to chop and change their weight losing strategies.<\/p>\n

\n\t\t\t<\/p>\n
\n
<\/div>\n<\/figure>\n

\t\t<\/a><\/p>\n<\/div>\n

How the Cleveland Clinic Conducted This Ozempic Study<\/h2>\n

7,938 overweight or obese adults in Ohio and Florida began treatment with either semaglutide (sold under brand names like Ozempic and Wegovy)<\/a> or tirzepatide (Mounjaro and Zepbound) and then stopped after three to 12 months. The scientists, led by Dr Gasoyan, then looked at the resulting weight loss, and the behavioral changes made by the participants.<\/p>\n

Key Findings From the Cleveland Clinic Study<\/h2>\n

Unlike the previous study that relied on randomized data, taking a real-world approach to following people\u2019s flexible lifestyles showed that people were less likely to rebound than previously thought. \u201cOur real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials,\u201d explained Dr. Gasoyan. The latest results showed:<\/p>\n